Larimar Therapeutics, Inc. (LRMR)

$4.09

-0.07 (-1.68%)
Rating:
Recommendation:
-
Symbol LRMR
Price $4.09
Beta 0.215
Volume Avg. 0.26M
Market Cap 177.005M
Shares () -
52 Week Range 2.58-6.85
1y Target Est -
DCF Unlevered LRMR DCF ->
DCF Levered LRMR LDCF ->
ROE -27.83% Sell
ROA -27.14% Sell
Operating Margin -
Debt / Equity 5.08% Neutral
P/E -5.60 Strong Sell
P/B 1.80 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LRMR news


Dr. Carole S. Ben-Maimon M.D.
Healthcare
Biotechnology
NASDAQ Global Market

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.